Gene

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Retrieved on: 
Monday, March 25, 2024
Ovarian cancer, Gene, Clinical Cancer Research, Erasmus MC, Data analysis, Colorectal cancer, Progression-free survival, Patient, Neoplasm, Triple-negative breast cancer, Tumor microenvironment, Manuscript, Pancreatic cancer, Cancer, Doctor of Philosophy, MD, Epithelium, PD-L1, AIM, Liver, RNA, Vaccine

The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.

Key Points: 
  • The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and tumors.
  • Post-Ampligen, the increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes.
  • Additionally, the changes in the tumor microenvironment we see in pancreatic cancer are similar to those we have seen in triple-negative breast cancer, ovarian cancer and colorectal cancer metastatic to the liver.

BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases

Retrieved on: 
Monday, March 25, 2024
Retina, Research, Gene, Development, IRD, Leber congenital amaurosis, Retinitis pigmentosa, Paratriathlon, Patient, Bayer, Foundation Fighting Blindness, Visual impairment, University, Wilfrid Sellars, Senior, IND, Therapy, IPSC, Usher syndrome, B cell, Pharmaceutical industry

The new cohort will include patients living with IRDs caused by mutations in multiple genes.

Key Points: 
  • The new cohort will include patients living with IRDs caused by mutations in multiple genes.
  • “BlueRock is developing a pipeline of cell therapies that we believe has great potential for restoring vision in people living with blindness caused by retinal disease,” said Ahmed Enayetallah, Senior Vice President and Head of Development for BlueRock Therapeutics.
  • Primary photoreceptor diseases are a subgroup of inherited retinal diseases that includes retinitis pigmentosa and cone- rod dystrophies.
  • OpCT-001 aims to restore vision loss caused by these diseases by replacing degenerated tissue in the retina with functional cells.

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

Retrieved on: 
Thursday, March 21, 2024
HCC, Research, AML, Logic, Partnership, Spark Therapeutics, SAN, Patient, Gene, SNTI, Acute myeloid leukemia, Doctor of Philosophy, IND, Investment, Investigational New Drug, Therapy, Hepatocellular carcinoma, FDA, Food, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • SENTI-202 for AML: In December 2023, Senti Bio announced the IND application for SENTI-202 was cleared by the U.S. Food and Drug Administration (“FDA”).
  • Cash, Cash Equivalents and Short-term Investments: As of December 31, 2023, Senti Bio held cash, cash equivalents and short-term investments of $35.9 million.
  • G&A Expenses: General and administrative expenses were $9.3 million for the fourth quarter of 2023, compared to $9.8 million for the same period in 2022.
  • Net Loss: Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023.

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Pneumonia, Survival, Survival rate, NSCLC, Disease, Mink, Webcast, Patient, VV, Research, Gene, Cancer, Lung cancer, White lung, IND, Immunity, Society, Therapy, Paclitaxel, TCR, Cell, FDA, Nature Communications, Pharmaceutical industry

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders

Retrieved on: 
Thursday, March 21, 2024
Disability, Gene, Enzyme, Seizure, Patient, DSM-IV codes, RNA, Messenger, Protein, Trial of the century, CPS1, UCD, Clinical trial, Therapy, Safety, Pharmacokinetics, Ammonia, Brain damage, Disorder, Blood, Pharmaceutical industry

“Most importantly, the clinical development of CMP-CPS-001 is a step toward potentially bringing a new, disease-modifying treatment to individuals living with UCDs.

Key Points: 
  • “Most importantly, the clinical development of CMP-CPS-001 is a step toward potentially bringing a new, disease-modifying treatment to individuals living with UCDs.
  • People with urea cycle disorders accumulate excessive ammonia in their blood, which may cause irreversible brain damage, disability, and seizures, and may be fatal.
  • CMP-CPS-001 targets carbamoyl phosphate synthetase 1 (CPS1), a key enzyme that catalyzes the first step of the urea cycle.
  • For more information about the Phase 1 clinical study of CMP-CPS-001, please visit clinicaltrials.gov ( NCT06247670 ).

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Wednesday, March 20, 2024
Toxicity, Administration, Gene, Editas Medicine, CD33, AML, Patient, IND, Food and Drug Administration, Research and development, HSC, Lymphocyte, Phenotype, Clinical trial, MRD, FDA, Antigen, Pharmaceutical industry

The first patient was dosed in January 2024, and multiple patients are expected to be dosed in the first half of 2024.

Key Points: 
  • The first patient was dosed in January 2024, and multiple patients are expected to be dosed in the first half of 2024.
  • The Company expects to report further engraftment and protection data from the VBP101 clinical trial in the second half of 2024.
  • The increase in G&A expenses was primarily attributable to an increase in personnel expenses, including an increase in share-based compensation expense.
  • Net Loss: Net loss for the fourth quarter of 2023 was $26.3 million, compared to $23.9 million for the fourth quarter of 2022, and for the year ended December 31, 2023, was $117.9 million, compared to $92.1 million for the year ended December 31, 2022.

Maryland-Based NanoBioFAB Wins Top Spot at Defense-Tech Startup Contest at AFCEA International Emerging Technology Conference

Retrieved on: 
Friday, March 15, 2024
Infection, Research, Artificial intelligence, AFCEA, Telehealth, Wound healing, Lens, Workforce, Marketing, Gene

The competition was part of AFCEA’s inaugural TechNet Emergence conference , held March 11-12 in Reston, Virginia.

Key Points: 
  • The competition was part of AFCEA’s inaugural TechNet Emergence conference , held March 11-12 in Reston, Virginia.
  • Fourteen companies made their technology pitches before panels of experts in start-up investment and venture capital over the two days.
  • Although the scoring was close, NanoBioFAB beat out the 13 other companies because its presentation demonstrated key success factors, said Anitha Raj, president of ARAR Technology and chair of AFCEA’s Technology Committee .
  • “It had the right technology for wound healing, which is one of the newest technologies using nano sensor technology,” Raj said.

Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm

Retrieved on: 
Thursday, March 14, 2024
ARK, Single-cell analysis, Genomics, Gene, Cell, Disease, Drug discovery, General partnership, Patient, Tissue, Khosla Ventures, AI, Biology, Therapy, Osteoporosis, Machine learning, Ark Invest, NVIDIA, Relation, Pharmaceutical industry

Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm

Key Points: 
  • Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
    London, March 2024 – Relation Therapeutics, a biotechnology company at the forefront of leveraging computational and experimental approaches to drug discovery, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.
  • David Roblin, CEO of Relation Therapeutics, said: "This financing is a significant milestone for Relation Therapeutics and underscores the confidence our investors have in our innovative approach to drug discovery and development.
  • Our technology platform, uniquely integrated with deep R&D expertise, places us in an outstanding position to transform drug discovery.
  • “We see Relation as a leader in the emerging techbio economy,” said Jason Pontin, General Partner at DCVC, who sits on Relation’s board.

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

Retrieved on: 
Wednesday, March 13, 2024
Lung cancer, Pollination, Bee, Metabolism, Culture, Gene, Algorithm, National Medal, Brain, Growth, Aditi, Gene expression, Survival, Cell, Bone marrow, Trustee, School, Research, Science News, RET, Highlands Ranch, Colorado, Death, Macrophage, ARD International Music Competition, Society, Student, Thought, Nobel Prize, STEM, CO, Cancer, MYC, ChatGPT, Machine learning, Society for Science, Liver, STS, Pharmaceutical industry

The 2024 finalists demonstrated extensive scientific knowledge through research and interviews while showcasing their commitment to addressing societal issues, passion for discovery, noteworthy leadership and community involvement.

Key Points: 
  • The 2024 finalists demonstrated extensive scientific knowledge through research and interviews while showcasing their commitment to addressing societal issues, passion for discovery, noteworthy leadership and community involvement.
  • This knowledge sheds light on what these algorithms are “thinking,” which can help make them more effective, fair and safe.
  • “Congratulations to the winners of this year’s Regeneron Science Talent Search,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • In total, Regeneron awarded $3.1 million in prizes through the Regeneron Science Talent Search 2024, including $2,000 to each of the top 300 scholars and their schools.

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

Retrieved on: 
Wednesday, March 13, 2024
ICST, ISCT, International Society, Disease, Science, Career Achievement Award, Patient, Knowledge, Lead, Gene, University College London, GMP, CGT, CSO, Vaccine

Boca Raton, Florida, March 13, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its Chief Scientific Officer and Co-Founder Mark Lowdell, Ph.D. has been awarded the Career Achievement Award in Cell and Gene Therapy by the International Society of Cell & Gene Therapy (ISCT), which the organization considers its highest honor. The award was announced as part of the annual ICST Major Awards announcement. Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.

Key Points: 
  • The award was announced as part of the annual ICST Major Awards announcement.
  • Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.
  • The ISCT is the elite organization in the field of cell and gene therapy,” said R.J. Tesi, M.D., INmune Bio’s Chief Executive Officer.
  • “I am honored to receive this most prestigious award in recognition of my life’s work and wish to thank the members of the ISCT.